Identa AI Stock Analysis
Want to see IDTA full AI Analyst Report?
Identa (IDTA) AI Stock Analysis
Identa
(Other OTC:IDTA)
The overall score of 61 reflects a significant conflict between strong financial fundamentals and extremely weak technicals. The company's financial health is a major positive, highlighted by a dramatic cash flow recovery and a much-improved balance sheet. However, the stock is in a severe downtrend, trading below all key moving averages with an oversold RSI, indicating the market is heavily discounting these fundamental improvements. The low P/E ratio supports the fundamental value but has not yet provided a floor for the stock price.
Identa (IDTA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $930.49K
- Dividend Yield
- ―
- Average Volume (3M)
- 4,252
- Price to Earnings (P/E)
- 6.5
- Beta (1Y)
- -1.38
- Revenue Growth
- 57.25%
- EPS Growth
- ―
- Country
- US
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Specialties
Identa Business Overview & Revenue Model
Company Description
IDenta Corp. operates as a detection and forensic science company. The company offers drug testing kits, explosives testing kits, aero chamber sniffer, forensic, urine drug testing, and saliva drug testing products. It provides its solutions to law e...
How the Company Makes Money
null
Identa Financial Statement Overview
Summary
Financial performance is strong, driven by a major cash flow turnaround and successful deleveraging. TTM free cash flow surged 260% to $253.5M, and the debt-to-equity ratio improved to 0.66. Revenue growth has returned to +10.2% with expanding margins, though net margins remain below their 2024 peak.
Income Statement
72PositiveBalance Sheet
68PositiveCash Flow
78Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.86M | 1.34M | 1.46M | 1.05M | 1.34M | 1.39M |
| Gross Profit | 958.46K | 686.57K | 756.46K | 662.98K | 983.39K | 1.02M |
| EBITDA | 254.66K | 128.96K | 328.40K | 57.13K | 199.56K | 135.57K |
| Net Income | 141.05K | 99.04K | 258.34K | 14.64K | 162.71K | 69.18K |
Balance Sheet | ||||||
| Total Assets | 2.38M | 1.92M | 1.66M | 1.53M | 1.56M | 1.23M |
| Cash, Cash Equivalents and Short-Term Investments | 669.76K | 379.42K | 735.95K | 264.29K | 368.90K | 347.15K |
| Total Debt | 661.18K | 645.20K | 640.23K | 785.37K | 820.28K | 511.63K |
| Total Liabilities | 1.08M | 1.04M | 921.01K | 1.01M | 1.10M | 799.32K |
| Stockholders Equity | 1.30M | 879.16K | 742.31K | 516.12K | 459.63K | 430.01K |
Cash Flow | ||||||
| Free Cash Flow | 253.53K | 40.28K | 555.85K | -151.97K | 61.56K | -221.97K |
| Operating Cash Flow | 284.25K | 56.94K | 561.89K | -137.63K | 94.31K | -88.95K |
| Investing Cash Flow | -87.01K | -48.05K | -260.40K | -8,154 | -8,611 | -133.02K |
| Financing Cash Flow | 276.22K | -43.78K | -151.47K | -23.53K | -63.95K | 28.02K |
Identa Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDTA, the sentiment is Negative. The current price of 0.23 is below the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.33, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 17.59 is Positive, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDTA.
Identa Peers Comparison
Overall Rating
- IDTA61Neutral
NDRA48Neutral
BIAF40Underperform
BNBX38Underperform
INBS34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IDTA | 61Neutral | $1.17M | 6.46 | 14.16% | ― | 57.25% | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| NDRA | 48Neutral | $7.15M | -0.74 | -224.80% | ― | ― | 98.17% |
| BIAF | 40Underperform | $4.41M | -0.04 | -331.02% | ― | -18.47% | 87.82% |
| BNBX | 38Underperform | $619.72K | -0.00 | -337.10% | ― | -27.39% | 99.29% |
| INBS | 34Underperform | $6.97M | -0.28 | -146.09% | ― | 36.55% | 60.09% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IDTA | Identa Corp | 0.23 | -0.04 | -13.21% | |
| BNBX | Bnb Plus Corp. | 0.08 | -2.67 | -97.09% | |
| NDRA | Endra Life Sciences | 4.64 | -1.56 | -25.16% | |
| INBS | Intelligent Bio Solutions Inc. | 1.93 | -4.99 | -72.11% | |
| BIAF | bioAffinity Technologies, Inc. | 2.34 | -21.36 | -90.13% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026